Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics

Title:Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics

Volume: 18 Issue: 13

Author(s): Matilde Y. Follo, Sara Mongiorgi, Carlo Finelli, Manuela Piazzi, Irene Faenza, Giulia Ramazzotti, Patrizia Santi, James A. McCubrey, Alberto M. Martelli, Lucio Cocco

Affiliation:

Keywords: Signal transduction, epigenetics, PI-PLCβ1, myelodysplastic syndromes, nucleus, apoptosis, hempoiesis, phospholipase, immunosuppressive, cytogenetic

Abstract: Among cellular second messengers inositides play key roles in signal transduction pathways. Indeed, nuclear phosphoinositide- specific phospholipase C (PI-PLC) β1 and Akt are involved in cell cycle progression and apoptosis. Nuclear lipid metabolism has raised interest in the last years, mainly because of its link with haematopoietic progenitor cells. Myelodysplastic syndromes (MDS) are stem-cell clonal diseases characterized by an impaired hempoiesis and a differentiation defect in one or more of the bone marrow lineages, often leading to progression to acute myeloid leukaemia (AML). The MDS evolution to AML is not completely understood but, at a molecular level, the nuclear inositide signalling pathways can play an important role in this process.

Cite this article as:

Ramazzotti, Patrizia Santi, James A. McCubrey, Alberto M. Martelli, Lucio Cocco Matilde Y. Follo, Sara Mongiorgi, Carlo Finelli, Manuela Piazzi, Irene Faenza, Giulia, Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics , Current Pharmaceutical Design 2012; 18 (13) . https://dx.doi.org/10.2174/138161212799859710